David Archer

Summary

Affiliation: Eastern Virginia Medical School
Country: USA

Publications

  1. ncbi request reprint Postmenopausal uterine bleeding profiles with two forms of continuous combined hormone replacement therapy
    Julia V Johnson
    Department of Obstetrics and Gynecology, University of Vermont College of Medicine, Burlington, VT 05405, USA
    Menopause 9:16-22. 2002
  2. ncbi request reprint Effect of tibolone and its metabolites on vascular endothelial growth factor isoforms 121 and 165 and thrombospondin-1 mRNA in Ishikawa cells
    Sebastian Mirkin
    Clinical Research Center, The Jones Institute for Reproductive Medicine, Eastern Virginia Medical School, Norfolk, VA 23507, USA
    Menopause 11:82-8. 2004
  3. doi request reprint Cardiovascular, cerebrovascular, and hepatic safety of desvenlafaxine for 1 year in women with vasomotor symptoms associated with menopause
    David F Archer
    Clinical Research Center, Eastern Virginia Medical School, Norfolk, VA 23507, USA
    Menopause 20:47-56. 2013
  4. doi request reprint Pharmacokinetics and adhesion of the Agile transdermal contraceptive patch (AG200-15) during daily exposure to external conditions of heat, humidity and exercise
    David F Archer
    Clinical Research Center, The Jones Institute for Reproductive Medicine, Eastern Virginia Medical School, Norfolk, VA 23507 1912, USA
    Contraception 87:212-9. 2013
  5. ncbi request reprint Postmenopausal skin and estrogen
    David F Archer
    Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, VA 23507, USA
    Gynecol Endocrinol 28:2-6. 2012
  6. doi request reprint Vascular dysfunction as a cause of endometrial bleeding
    David F Archer
    Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, VA 23507, USA
    Gynecol Endocrinol 28:688-93. 2012
  7. doi request reprint Transdermal estradiol gel for the treatment of symptomatic postmenopausal women
    David F Archer
    Jones Institute for Reproductive Medicine, Eastern Virginia Medical School, Norfolk, VA 23507 1912, USA
    Menopause 19:622-9. 2012
  8. doi request reprint Ethinyl estradiol and levonorgestrel pharmacokinetics with a low-dose transdermal contraceptive delivery system, AG200-15: a randomized controlled trial
    David F Archer
    Clinical Research Center, The Jones Institute for Reproductive Medicine, Eastern Virginia Medical School, Norfolk, VA 23507 1912, USA
    Contraception 85:595-601. 2012
  9. ncbi request reprint Lower doses of oral estrogen and progestogens as treatment for postmenopausal women
    David F Archer
    Department of Obstetrics and Gynecology, Eastern Virginia Medical School, 601 Colley Avenue, Norfolk, VA 23507, USA
    Semin Reprod Med 23:188-95. 2005
  10. ncbi request reprint Neoplasia of the female reproductive tract: effects of hormone therapy
    David F Archer
    Department of Obstetrics and Gynecology, Director, CONRAD Clinical Research Center, Eastern Virginia Medical School, 601 Colley Avenue, Norfolk, VA 23507, USA
    Endocrine 24:259-63. 2004

Research Grants

Detail Information

Publications67

  1. ncbi request reprint Postmenopausal uterine bleeding profiles with two forms of continuous combined hormone replacement therapy
    Julia V Johnson
    Department of Obstetrics and Gynecology, University of Vermont College of Medicine, Burlington, VT 05405, USA
    Menopause 9:16-22. 2002
    ..5 mg norethindrone acetate (Activella; E(2)/NETA group), a newly available CCHRT preparation, over a 6-month period...
  2. ncbi request reprint Effect of tibolone and its metabolites on vascular endothelial growth factor isoforms 121 and 165 and thrombospondin-1 mRNA in Ishikawa cells
    Sebastian Mirkin
    Clinical Research Center, The Jones Institute for Reproductive Medicine, Eastern Virginia Medical School, Norfolk, VA 23507, USA
    Menopause 11:82-8. 2004
    ....
  3. doi request reprint Cardiovascular, cerebrovascular, and hepatic safety of desvenlafaxine for 1 year in women with vasomotor symptoms associated with menopause
    David F Archer
    Clinical Research Center, Eastern Virginia Medical School, Norfolk, VA 23507, USA
    Menopause 20:47-56. 2013
    ..The current study was designed to estimate these events in desvenlafaxine versus placebo in a larger population followed for 1 year...
  4. doi request reprint Pharmacokinetics and adhesion of the Agile transdermal contraceptive patch (AG200-15) during daily exposure to external conditions of heat, humidity and exercise
    David F Archer
    Clinical Research Center, The Jones Institute for Reproductive Medicine, Eastern Virginia Medical School, Norfolk, VA 23507 1912, USA
    Contraception 87:212-9. 2013
    ....
  5. ncbi request reprint Postmenopausal skin and estrogen
    David F Archer
    Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, VA 23507, USA
    Gynecol Endocrinol 28:2-6. 2012
    ..This review explores the potential for targeted estrogen replacement as a therapeutic option for long-term skin management in postmenopausal women...
  6. doi request reprint Vascular dysfunction as a cause of endometrial bleeding
    David F Archer
    Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, VA 23507, USA
    Gynecol Endocrinol 28:688-93. 2012
    ..Heavy menstrual bleeding (HMB) and the spotting and bleeding (S/B) associated with the use of hormonal contraceptives are distinct entities affecting endometrial vasculature and hemostasis...
  7. doi request reprint Transdermal estradiol gel for the treatment of symptomatic postmenopausal women
    David F Archer
    Jones Institute for Reproductive Medicine, Eastern Virginia Medical School, Norfolk, VA 23507 1912, USA
    Menopause 19:622-9. 2012
    ..The aim of this study was to determine the efficacy, safety, and lowest practical dose of a transdermal estradiol gel in the treatment of symptomatic postmenopausal women...
  8. doi request reprint Ethinyl estradiol and levonorgestrel pharmacokinetics with a low-dose transdermal contraceptive delivery system, AG200-15: a randomized controlled trial
    David F Archer
    Clinical Research Center, The Jones Institute for Reproductive Medicine, Eastern Virginia Medical School, Norfolk, VA 23507 1912, USA
    Contraception 85:595-601. 2012
    ....
  9. ncbi request reprint Lower doses of oral estrogen and progestogens as treatment for postmenopausal women
    David F Archer
    Department of Obstetrics and Gynecology, Eastern Virginia Medical School, 601 Colley Avenue, Norfolk, VA 23507, USA
    Semin Reprod Med 23:188-95. 2005
    ..The impact of lower doses of hormones on heart disease, and venous thromboembolism and stroke remain to be determined in future studies...
  10. ncbi request reprint Neoplasia of the female reproductive tract: effects of hormone therapy
    David F Archer
    Department of Obstetrics and Gynecology, Director, CONRAD Clinical Research Center, Eastern Virginia Medical School, 601 Colley Avenue, Norfolk, VA 23507, USA
    Endocrine 24:259-63. 2004
    ..The data suggest a possible increase in ovarian epithelial tumors with >10 years use of estrogen only. There is no evidence of a change in the incidence of uterine cervical neoplasia with either estrogen or progestin...
  11. doi request reprint Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women
    David F Archer
    CONRAD Clinical Research Center, Eastern Virginia Medical School, Norfolk, VA 23507, USA
    Menopause 16:1109-15. 2009
    ..The aim of this study was to evaluate the endometrial, ovarian, and breast safety of bazedoxifene used as a treatment for postmenopausal osteoporosis...
  12. doi request reprint Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety
    David F Archer
    Clinical Research Center, Eastern Virginia Medical School, Norfolk, VA, USA
    Am J Obstet Gynecol 200:238.e1-238.e10. 2009
    ..The objective of the study was to assess the efficacy and safety of desvenlafaxine (administered as desvenlafaxine succinate) for the treatment of vasomotor symptoms...
  13. ncbi request reprint Interleukin-6 and tumor necrosis factor-alpha concentrations in the intrauterine cavity of postmenopausal women using an intrauterine delivery system releasing progesterone. A possible mechanism of action of the intrauterine device
    D F Archer
    Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, USA
    Contraception 59:175-9. 1999
    ..IL-6 and TNF-alpha levels were increased in the intrauterine cavity of postmenopausal women with an IDS-P. These data suggest that secreted cytokines could be a potential mechanism of IUD contraceptive efficacy...
  14. doi request reprint Effects of ethinyl estradiol and ibuprofen compared to placebo on endometrial bleeding, cervical mucus and the postcoital test in levonorgestrel subcutaneous implant users
    David F Archer
    CONRAD Clinical Research Center, Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, VA 23507, USA
    Contraception 78:106-12. 2008
    ..Women experiencing excessive S/B were enrolled in a multicenter prospective randomized study using EE, IBU or PL...
  15. ncbi request reprint Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial
    David F Archer
    CONRAD Clinical Research Center, 601 Colley Avenue, Norfolk, VA 23507, USA
    Menopause 12:716-27. 2005
    ....
  16. ncbi request reprint Tibolone histology of the endometrium and breast endpoints study: design of the trial and endometrial histology at baseline in postmenopausal women
    David F Archer
    Department of Obstetrics and Gynecology, Contraceptive Research and Development Program Clinical Research Center, Eastern Virginia Medical School, Norfolk, Virginia 23507, USA
    Fertil Steril 88:866-78. 2007
    ..To address the endometrial safety of tibolone...
  17. ncbi request reprint Drospirenone-containing hormone therapy for postmenopausal women. Perspective on current data
    David F Archer
    Department of Obstetrics and Gynecology and CONRAD Clinical Research Center, Eastern Virginia Medical School, Norfolk, Virginia, USA
    J Reprod Med 52:159-64. 2007
    ..In addition to providing effective and safe relief of menopausal symptoms, the combination has a beneficial effect on blood pressure and weight gain...
  18. ncbi request reprint Endometrial bleeding during hormone therapy: the effect of progestogens
    David F Archer
    Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, VA, USA
    Maturitas 57:71-6. 2007
    ..No good therapeutic option to control the bleeding or spotting exists at this time. Evaluation and monitoring of the patient regarding endometrial safety is of paramount importance...
  19. ncbi request reprint Menstrual-cycle-related symptoms: a review of the rationale for continuous use of oral contraceptives
    David F Archer
    Contraceptive Research and Development Program, Clinical Research Center, Eastern Virginia Medical School, Norfolk, VA 23507, USA
    Contraception 74:359-66. 2006
    ..For women who do not wish to become pregnant, a continuous OC regimen should be an available option...
  20. ncbi request reprint Endometrial effects of tibolone
    David F Archer
    CONRAD Clinical Research Center, 601 Colley Avenue, Norfolk, Virginia 23507, USA
    J Clin Endocrinol Metab 92:911-8. 2007
    ..25 or 2.5 mg/d). Tibolone was compared with continuous combined conjugated equine estrogen (CEE) plus medroxyprogesterone acetate (MPA) (0.625 + 2.5 mg/d)...
  21. ncbi request reprint Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results
    David F Archer
    CONRAD Clinical Research Center, Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, VA 23507, USA
    Contraception 74:439-45. 2006
    ..This study was conducted to evaluate the safety and efficacy of a continuous daily regimen of levonorgestrel (LNG) 90 microg/ethinyl estradiol (EE) 20 microg (continuous LNG/EE)...
  22. doi request reprint Efficacy and tolerability of local estrogen therapy for urogenital atrophy
    David F Archer
    CONRAD Clinical Research Center, Eastern Virginia Medical School, Norfolk, VA, USA
    Menopause 17:194-203. 2010
    ....
  23. doi request reprint Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women
    David F Archer
    CONRAD Clinical Research Center, Eastern Virginia Medical School, Norfolk, Virginia 23507, USA
    Fertil Steril 92:1039-44. 2009
    ..To evaluate the effect of bazedoxifene/conjugated estrogens (BZA/CE), a tissue selective estrogen complex, on uterine bleeding in postmenopausal women...
  24. doi request reprint Ovarian activity and safety of a novel levonorgestrel/ethinyl estradiol continuous oral contraceptive regimen
    David F Archer
    CONRAD Clinical Research Center, Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, VA 23507, USA
    Contraception 80:245-53. 2009
    ..A continuous regimen of oral levonorgestrel (LNG) 90 mcg/ethinyl estradiol (EE) 20 mcg was evaluated for inhibition of ovulation, time to return to ovulation after stopping treatment and safety...
  25. ncbi request reprint A randomized comparison of continuous combined transdermal delivery of estradiol-norethindrone acetate and estradiol alone for menopause. CombiPatch Study Group
    D F Archer
    Clinical Research Center, Eastern Virginia Medical School, Norfolk 23507 1627, USA
    Obstet Gynecol 94:498-503. 1999
    ..To determine whether a continuous estradiol-norethindrone acetate transdermal delivery system reduces incidence of endometrial hyperplasia in postmenopausal women more than transdermal estradiol (E2) alone...
  26. ncbi request reprint Endometrial histology during use of a low-dose estrogen-desogestrel oral contraceptive with a reduced hormone-free interval
    D F Archer
    Jones Institute for Reproductive Medicine, Eastern Virginia Medical School, Norfolk, VA 23507 1627, USA
    Contraception 60:151-4. 1999
    ..The endometrial histologic findings observed in this study were similar to those observed during the use of 21-day combination oral contraceptive regimens...
  27. ncbi request reprint Hormone replacement therapy: effect of progestin dose and time since menopause on endometrial bleeding
    D F Archer
    Jones Institute for Reproductive Medicine, Eastern Virginia Medical Center, Norfolk, Virginia 23507 1912, USA
    Obstet Gynecol 96:899-905. 2000
    ..To analyze the effects of two continuous combined hormone replacement regimens on bleeding profiles in postmenopausal women, based on progestin dose and time since the patient's last spontaneous menstrual period...
  28. ncbi request reprint Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding
    D F Archer
    Jones Institute for Reproductive Medicine, Norfolk, Virginia 23507, USA
    Fertil Steril 75:1080-7. 2001
    ..To evaluate vaginal bleeding profiles with lower doses of conjugated equine estrogens (CEE) and medroxyprogesterone acetate (MPA) as continuous combined therapy...
  29. ncbi request reprint The effect of the duration of progestin use on the occurrence of endometrial cancer in postmenopausal women
    D F Archer
    Department of Obstetrics and Gynecology, and Clinical Research Center, Eastern Virginia Medical School, Norfolk, Virginia, USA
    Menopause 8:245-51. 2001
    ..The addition of a progestin to ERT reduces the incidence of endometrial cancer. The duration of progestin administration is more important than the dose...
  30. doi request reprint A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause
    David F Archer
    Clinical Research Center, Eastern Virginia Medical School, Norfolk, VA 23507, USA
    Am J Obstet Gynecol 200:172.e1-10. 2009
    ..The objective of the study was to assess the efficacy and safety of desvenlafaxine (administered as desvenlafaxine succinate) for menopausal vasomotor symptoms...
  31. doi request reprint Tissue-selective estrogen complexes: a promising option for the comprehensive management of menopausal symptoms
    David F Archer
    Clinical Research Center, Jones Institute for Reproductive Medicine, Eastern Virginia Medical School, Norfolk, Virginia 23507 1912, USA
    Drugs Aging 27:533-44. 2010
    ....
  32. ncbi request reprint Low-dose hormone therapy for postmenopausal women
    David F Archer
    Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, USA
    Clin Obstet Gynecol 46:317-24. 2003
  33. ncbi request reprint Percutaneous 17beta-estradiol gel for the treatment of vasomotor symptoms in postmenopausal women
    David F Archer
    The Jones Institute for Reproductive Medicine, 601 Colley Ave, Second Floor, Norfolk, VA 23507 1627, USA
    Menopause 10:516-21. 2003
    ..To determine the efficacy and tolerability of two strengths of percutaneous 17beta-estradiol in a hydroalcoholic gel and placebo in controlling vasomotor symptoms of menopause...
  34. ncbi request reprint Effects of levonorgestrel, medroxyprogesterone acetate, norethindrone, and 17beta-estradiol on vascular endothelial growth factor isomers 121 and 165 in Ishikawa cells
    David F Archer
    The Clinical Research Center, The Jones Institute for Reproductive Medicine, Eastern Virginia Medical School, Norfolk, Virginia 23507, USA
    Fertil Steril 81:165-70. 2004
    ..To determine the effect of 17beta-E(2), levonorgestrel, medroxyprogesterone acetate, and norethindrone on the expression of vascular endothelial growth factor (VEGF) isoforms 121 and 165 in Ishikawa cells in vitro...
  35. doi request reprint Endometrial bleeding in postmenopausal women: with and without hormone therapy
    David F Archer
    The Jones Institute for Reproductive Medicine, Eastern Virginia Medical School, Norfolk, VA 23507, USA
    Menopause 18:416-20. 2011
    ..The major cause of hormone therapy-related bleeding is unknown. Alterations in angiogenic factors that could result in vascular dysfunction and vessel breakdown provide a working hypothesis as to the potential cause of vessel breakdown...
  36. doi request reprint Tailoring combination oral contraceptives to the individual woman
    David F Archer
    Obstetrics and Gynecology, Eastern Virginia Medical School, 601 Colley Avenue, Norfolk, VA 23507, USA
    J Womens Health (Larchmt) 20:879-91. 2011
    ..New formulations, including extended-cycle or continuous-use COCs or those that use a natural estrogen, estradiol, may offer improvements over their predecessors...
  37. ncbi request reprint Medical decisions regarding hormone therapy for menopausal women are significantly influenced by the media
    David F Archer
    Department of Obstetrics and Gynecology, CONRAD Clinical Research Center, Eastern Virginia Medical School, Norfolk, Virginia 23507, USA
    Pharmacoepidemiol Drug Saf 16:28-31. 2007
  38. ncbi request reprint Effects of tibolone and its metabolites on Angiopoietin-1, Tie-2 and tumor necrosis factor-alpha mRNA in Ishikawa cells. Implication for tibolone's effects on the endometrium
    Sebastian Mirkin
    CONRAD Clinical Research Center, Jones Institute for Reproductive Medicine, Eastern Virginia Medical School, USA
    Maturitas 57:338-46. 2007
    ..We hypothesized that differential effects on angiogenic factors or inflammatory cytokines by individual hormones may be related to the endometrial bleeding in postmenopausal women using hormone therapy...
  39. ncbi request reprint Effects of mifepristone on vascular endothelial growth factor and thrombospondin-1 mRNA in Ishikawa cells: implication for the endometrial effects of mifepristone
    Sebastian Mirkin
    The Contraceptive Research and Development Program, Clinical Research Center, The Jones Institute for Reproductive Medicine Eastern Virginia Medical School, 601 Colley Avenue, Norfolk, VA 23507, USA
    Contraception 70:327-33. 2004
    ..We hypothesized, based on these data, that the clinical finding of endometrial antiproliferative effect and low vaginal bleeding rate observed in women using mifepristone may be related to lack of stimulation of these angiogenic factors...
  40. ncbi request reprint Hormone therapy and endometrial angiogenesis
    Sebastian Mirkin
    The Jones Institute for Reproductive Medicine, CONRAD Clinical Research Center, Eastern Virginia Medical School, Norfolk, Virginia 23507, USA
    Climacteric 6:273-7. 2003
    ..These alterations could induce a unique pro angiogenic activity in the endometrial capillary plexus, with consequent aberrant vasculogenesis, which may result in irregular endometrial bleeding...
  41. ncbi request reprint Effect of 17 beta-estradiol, progesterone, synthetic progestins, tibolone, and tibolone metabolites on vascular endothelial growth factor mRNA in breast cancer cells
    Sebastian Mirkin
    The Contraceptive Research and Development Program, The Clinical Research Center, The Jones Institute for Reproductive Medicine, Eastern Virginia Medical School, Norfolk, Virginia 23507, USA
    Fertil Steril 84:485-91. 2005
    ....
  42. doi request reprint Effects of doxycycline on serum and endometrial levels of MMP-2, MMP-9 and TIMP-1 in women using a levonorgestrel-releasing subcutaneous implant
    Shumei Zhao
    Department of Obstetrics and Gynecology, CONRAD Clinical Research Center, Jones Institute for Reproductive Medicine, Eastern Virginia Medical School, Norfolk, VA 23507, USA
    Contraception 79:469-78. 2009
    ..Endometrial spotting and/or bleeding (ESB) occurs in levonorgestrel subcutaneous implant (LNG SI) users. Matrix metalloproteinases (MMPs) may play a role in ESB...
  43. ncbi request reprint Effect of raloxifene, 17beta-estradiol, and progesterone on mRNA for vascular endothelial growth factor isoforms 121 and 165 and thrombospondin-1 in Ishikawa cells
    Francisco J Navarro
    The Clinical Research Center, The Jones Institute for Reproductive Medicine, Eastern Virginia Medical School, Norfolk, Virginia, USA
    Fertil Steril 79:1409-15. 2003
    ..To compare the mRNA expression of vascular endothelial growth factor (VEGF) 121 and 165 isoforms and thrombospondin-1 (TSP-1) after raloxifene, 17beta-E(2), and P administration in cultured Ishikawa cells...
  44. ncbi request reprint A comparison of techniques to assess cervicovaginal irritation and evaluation of the variability between two observers
    Susan A Ballagh
    CONRAD Clinical Research Center, Eastern Virginia Medical School, 601 Colley Avenue, Norfolk, VA 23507, USA
    Contraception 70:241-9. 2004
    ..Colposcopy is used to evaluate effects of new vaginal products on cervicovaginal epithelium as part of the US Food and Drug Administration-mandated product approval process, yet few aspects of its use have been investigated...
  45. doi request reprint Effects of progesterone, levonorgestrel and medroxyprogesterone acetate on apoptosis in human endometrial endothelial cells
    Chainarong Choksuchat
    CONRAD Clinical Research Center, Department of Obstetrics and Gynecology, Eastern Virginia Medical School, Norfolk, VA 23507, USA
    Contraception 79:139-45. 2009
    ..We evaluated apoptosis in human endometrial endothelial cells (HEECs) incubated with progesterone, levonorgestrel (LNG) and medroxyprogesterone acetate (MPA)...
  46. doi request reprint Cervicovaginal colposcopic lesions associated with 5 nonoxynol-9 vaginal spermicide formulations
    Bryna Harwood
    Department of Obstetrics and Gynecology, University of Illinois at Chicago College of Medicine, Chicago, IL, USA
    Am J Obstet Gynecol 198:32.e1-7. 2008
    ..This study was undertaken to compare the colposcopic appearance of the cervicovaginal epithelium with spermicide use vs condom use in a low-risk population...
  47. ncbi request reprint The impact of improved compliance with a weekly contraceptive transdermal system (Ortho Evra) on contraceptive efficacy
    David F Archer
    Contraceptive Research and Development Program, Clinical Research Center, Eastern Virginia Medical School, Norfolk, VA, USA
    Contraception 69:189-95. 2004
    ..Method compliance determines the proportion of perfect and imperfect dosing cycles, and together can form the basis for evaluating differences in efficacy based on differences in compliance...
  48. pmc Single and multiple exposure tolerance study of polystyrene sulfonate gel: a phase I safety and colposcopy study
    Christine K Mauck
    CONRAD, Eastern Virginia Medical School, 1611 North Kent Street, Suite 806, Arlington 22209, USA
    Contraception 70:77-83. 2004
    ..To evaluate symptoms and signs of genital irritation, vaginal leakage and acceptability of polystyrene sulfonate (PSS), which is being studied as a vaginal contraceptive and microbicide...
  49. ncbi request reprint Doxycycline alters the expression of inflammatory and immune-related cytokines and chemokines in human endometrial cells: implication in irregular uterine bleeding
    Rongxiu Li
    Department of Obstetrics and Gynecology, University of Florida, Gainesville 32610 0294, USA
    Hum Reprod 21:2555-63. 2006
    ..Evidence suggests that in addition to its antimicrobial property, doxycycline (Dox) acts as an anti-inflammatory agent mainly through the suppression of pro-inflammatory mediators...
  50. ncbi request reprint Assessment of compliance with a weekly contraceptive patch (Ortho Evra/Evra) among North American women
    David F Archer
    Eastern Virginia Medical School, Norfolk, Virginia, USA
    Fertil Steril 77:S27-31. 2002
    ..To determine compliance with the contraceptive patch (Ortho Evra/Evra) overall and by age among women in North America and to compare rates of perfect use with those of an established oral contraceptive...
  51. ncbi request reprint A phase I comparative postcoital testing study of three concentrations of C31G
    Christine K Mauck
    CONRAD, Eastern Virginia Medical School, 1611 North Kent Street, Suite 806, Arlington, VA 22209, USA
    Contraception 70:227-31. 2004
    ..5%, 1.0% and 1.7%, administered as a 3.5-mL dose of a vaginal gel to prevent sperm from entering mid-cycle cervical mucus. Irritation of the genitalia and acceptability were also assessed...
  52. pmc FemCap with removal strap: ease of removal, safety and acceptability
    Christine K Mauck
    CONRAD, Eastern Virginia Medical School, Arlington, VA 22209, USA
    Contraception 73:59-64. 2006
    ..This trial assessed whether the new design reduced removal difficulties and had any effects on dislodgment, genital pain/discomfort, safety, and acceptability...
  53. ncbi request reprint Role of the nonhuman primate for research related to women's health
    David F Archer
    CONRAD Clinical Research Center, Norfolk, VA, USA
    ILAR J 45:212-9. 2004
    ..These findings allow us to utilize the nonhuman primate as the most relevant model in the animal world for the study of human disease processes...
  54. ncbi request reprint Doxycycline alters the expression of matrix metalloproteases in the endometrial cells exposed to ovarian steroids and pro-inflammatory cytokine
    Rongxiu Li
    Department of Ob Gyn, University of Florida, Gainesville, FL 32610, USA
    J Reprod Immunol 73:118-29. 2007
    ....
  55. ncbi request reprint Effects of levonorgestrel, medroxyprogesterone acetate, norethindrone, progesterone, and 17beta-estradiol on thrombospondin-1 mRNA in Ishikawa cells
    Sebastian Mirkin
    Fertil Steril 82:220-2. 2004
    ..Progestins had less effects on TSP-1 mRNA compared to P, in Ishikawa cells, and this difference in TSP-1 expression by individual progestins may be associated with the irregular bleeding seen in women using progestin-only contraception...
  56. ncbi request reprint Ortho Evra/Evra versus oral contraceptives: follicular development and ovulation in normal cycles and after an intentional dosing error
    Roger A Pierson
    Obstetrics, Gynecology, and Reproductive Sciences, University of Saskatchewan, Saskatoon, Canada
    Fertil Steril 80:34-42. 2003
    ..To compare the effects of the contraceptive patch to oral contraceptives (OCs) on follicular size and incidence of ovulation in normal cycles and after dosing errors...
  57. pmc Continuous combined hormone replacement therapy and endometrial hyperplasia
    David F Archer
    BMJ 325:231-2. 2002
  58. ncbi request reprint Safety and efficacy of Implanon, a single-rod implantable contraceptive containing etonogestrel
    Sidney Funk
    Radiant Research, Atlanta, GA 30342, USA
    Contraception 71:319-26. 2005
    ..The safety and efficacy of a single-rod implantable contraceptive containing etonogestrel (Implanontrade mark) were investigated in a multicenter clinical trial...
  59. ncbi request reprint Drospirenone, a progestin with added value for hypertensive postmenopausal women
    David F Archer
    Menopause 14:352-4. 2007
  60. ncbi request reprint Estradiol gel: review of the pharmacology, pharmacokinetics, efficacy, and safety in menopausal women
    Mark Naunton
    Department of Pharmacotherapy and Pharmaceutical Care, University of Groningen, Groningen, The Netherlands
    Menopause 13:517-27. 2006
    ..To review the pharmacology, pharmacokinetics, safety, and efficacy of a gel containing estradiol that is applied to the skin...
  61. ncbi request reprint Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 micro g (Loestrin 24 Fe)
    Steven T Nakajima
    Division of Reproductive Endocrinology and Infertility, Department of Obstetrics, Gynecology and Women s Health, University of Louisville, Louisville, KY 40202, USA
    Contraception 75:16-22. 2007
    ..Extending the duration of active hormonal treatment may reduce the frequency of intracyclic bleeding/spotting while maintaining efficacy and tolerability...
  62. doi request reprint Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol for contraception and control of menstrual symptoms
    Jeffrey T Jensen
    Oregon Health and Science University, Department of Ob Gyn, UHN 70, 3181 SW Sam Jackson Park Road, Portland, Oregon 97239, USA
    Expert Opin Pharmacother 9:319-27. 2008
    ....
  63. ncbi request reprint Progestogens: effects on clinical and biochemical parameters in postmenopausal women
    David F Archer
    Menopause 12:484-7. 2005
  64. ncbi request reprint Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women
    Sheila Ronkin
    Wyeth Research, Collegeville, Pennsylvania 19426, USA
    Obstet Gynecol 105:1397-404. 2005
    ..To assess the endometrial effects of bazedoxifene acetate in healthy postmenopausal women...
  65. pmc Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society
    Wulf H Utian
    Menopause 15:584-602. 2008
    ....
  66. pmc Progesterone receptor modulator for emergency contraception: a randomized controlled trial
    Mitchell D Creinin
    Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh and Magee Womens Research Institute, Pittsburgh, Pennsylvania 15213, USA
    Obstet Gynecol 108:1089-97. 2006
    ..Compare the efficacy and adverse effects of CDB-2914, a new progesterone receptor modulator, to levonorgestrel for emergency contraception...
  67. ncbi request reprint Contraceptive efficacy of a novel spermicidal microbicide used with a diaphragm: a randomized controlled trial
    Kurt T Barnhart
    University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Obstet Gynecol 110:577-86. 2007
    ..The objective of this study was to assess the gel's contraceptive effects, safety, and acceptability...

Research Grants5

  1. DOXYCYCLINE FOR BLEEDING IN PROGESTIN ONLY CONTRACEPTORS
    David Archer; Fiscal Year: 2006
    ..If successful, DOX treatment could become an important adjuvant for treatment of this and possibly other inflammatory disorders effecting reproductive tract tissues. ..